These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 15886474)
1. A phase I study of prolonged ambulatory infusion of Ifosfamide with oral mesna. Olver I; Keefe D; Myers M; Caruso D Chemotherapy; 2005 May; 51(2-3):142-6. PubMed ID: 15886474 [TBL] [Abstract][Full Text] [Related]
2. High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma. Talbot SM; Rankin C; Taub RN; Balcerzak SP; Bhoopalam N; Chapman RA; Baker LH; Middleman EL; Antman KH Cancer; 2003 Jul; 98(2):331-6. PubMed ID: 12872353 [TBL] [Abstract][Full Text] [Related]
3. Phase I trial of a 24-h continuous infusion of ifosfamide/mesna in acute lymphoblastic leukemia. Otero JC; Solidoro A; Casanova L; Vallejos C; Rodriguez W J Exp Ther Oncol; 1996 Mar; 1(2):84-7. PubMed ID: 9414391 [TBL] [Abstract][Full Text] [Related]
4. Urine mesna excretion after intravenous and oral dosing in ifosfamide-treated children. Goren MP; Epelman S; Bush DA Cancer Chemother Pharmacol; 2004 Sep; 54(3):237-40. PubMed ID: 15184993 [TBL] [Abstract][Full Text] [Related]
6. Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients. Coriat R; Mir O; Camps S; Ropert S; Billemont B; Leconte M; Larousserie F; Anract P; Alexandre J; Goldwasser F Cancer Chemother Pharmacol; 2010 Feb; 65(3):491-5. PubMed ID: 19588140 [TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma. Kushner DM; Webster KD; Belinson JL; Rybicki LA; Kennedy AW; Markman M Gynecol Oncol; 2000 Aug; 78(2):221-7. PubMed ID: 10926807 [TBL] [Abstract][Full Text] [Related]
8. Ambulatory 4-day continuous-infusion schedule of high-dose ifosfamide with mesna uroprotection and granulocyte colony-stimulating factor in advanced solid tumours: a phase I study. Toma S; Palumbo R; Comandone A; Oliva C; Vincenti M; Bumma C; Rosso R Ann Oncol; 1995 Feb; 6(2):193-6. PubMed ID: 7540421 [TBL] [Abstract][Full Text] [Related]
9. Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules. Antman KH; Elias A; Ryan L Semin Oncol; 1990 Apr; 17(2 Suppl 4):68-73. PubMed ID: 2110386 [TBL] [Abstract][Full Text] [Related]
10. Phase I trial of dose-escalated paclitaxel and carboplatin in combination with ifosfamide and filgrastim: preliminary results. Palackdharry CS Semin Oncol; 1996 Jun; 23(3 Suppl 6):78-83. PubMed ID: 8677455 [TBL] [Abstract][Full Text] [Related]
11. High-dose ifosfamide with hematopoietic growth factor support in advanced bone and soft tissue sarcomas. Yalcin B; Pamir A; Buyukcelik A; Utkan G; Akbulut H; Demirkazik A; Icli F Exp Oncol; 2004 Dec; 26(4):320-5. PubMed ID: 15627067 [TBL] [Abstract][Full Text] [Related]
13. Combined intravenous and oral mesna in outpatients treated with ifosfamide. Goren MP; McKenna LM; Goodman TL Cancer Chemother Pharmacol; 1997; 40(5):371-5. PubMed ID: 9272112 [TBL] [Abstract][Full Text] [Related]
14. Phase II study of continuous-infusion high-dose ifosfamide in advanced and/or metastatic pretreated soft tissue sarcomas. Palumbo R; Palmeri S; Antimi M; Gatti C; Raffo P; Villani G; Toma S Ann Oncol; 1997 Nov; 8(11):1159-62. PubMed ID: 9426338 [TBL] [Abstract][Full Text] [Related]
15. Preliminary report on a phase I study of ifosfamide and vinorelbine (navelbine) in advanced non-small cell lung cancer. Masters GA; Hoffman PC; Drinkard LC; Watson S; Samuels BL; Golomb HM; Vokes EE Semin Oncol; 1996 Apr; 23(2 Suppl 5):11-8. PubMed ID: 8610230 [TBL] [Abstract][Full Text] [Related]
16. Intravenous ifosfamide/mesna is associated with depletion of plasma thiols without depletion of leukocyte glutathione. Pendyala L; Creaven PJ; Schwartz G; Meropol NJ; Bolanowska-Higdon W; Zdanowicz J; Murphy M; Perez R Clin Cancer Res; 2000 Apr; 6(4):1314-21. PubMed ID: 10778956 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of ifosfamide plus mesna as first-line chemotherapy in women with metastatic breast cancer. Ingle JN; Krook JE; Mailliard JA; Hartmann LC; Wieand HS Am J Clin Oncol; 1995 Dec; 18(6):498-501. PubMed ID: 8526193 [TBL] [Abstract][Full Text] [Related]
18. Ifosfamide bolus followed by five days continuous infusion in extensively pretreated patients with advanced breast cancer: a phase II study. Bisagni G; Boni C; Manenti AL; Moretti G; Rondini E; Sassi M; Zadro A; Savoldi L Tumori; 1998; 84(6):659-61. PubMed ID: 10080671 [TBL] [Abstract][Full Text] [Related]
20. Ifosfamide in the treatment of soft-tissue sarcomas: experience at the West German Tumor Center, Essen. Schütte J; Kellner R; Seeber S Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S194-8. PubMed ID: 8453697 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]